Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment

the InDDEx study

Howard H. Feldman, Steven Ferris, Bengt Winblad, Nikolaos Sfikas, Linda Mancione, Yunsheng He, Sibel Tekin, Alistair Burns, Jeffrey Cummings, Teodoro del Ser, Domenico Inzitari, Jean Marc Orgogozo, Heinrich Sauer, Philip Scheltens, Elio Scarpini, Nathan Herrmann, Martin Farlow, Steven Potkin, H. Cecil Charles, Nick C. Fox & 1 others Roger Lane

Research output: Contribution to journalArticle

225 Citations (Scopus)

Abstract

Objective: To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline. Methods: The study was a double-blind, randomised, placebo-controlled trial of up to 48 months. All patients had MCI operationally defined by having cognitive symptoms, a global clinical dementia rating stage of 0·5, a score of less than 9 on the New York University delayed paragraph recall test, and by not meeting the diagnostic criteria for AD. Primary efficacy variables were time to clinical diagnosis of AD, and change in performance on a cognitive test battery. This study is registered with the US National Institutes of Health clinical trials database (ClinicalTrials.gov), number NCT00000174. Findings: Of 1018 study patients enrolled, 508 were randomly assigned to rivastigmine and 510 to placebo; 17·3% of patients on rivastigmine and 21·4% on placebo progressed to AD (hazard ratio 0·85 [95% CI 0·64-1·12]; p=0·225). There was no significant difference between the rivastigmine and placebo groups on the standardised Z score for the cognitive test battery measured as mean change from baseline to endpoint (-0·10 [95% CI -0·63 to 0·44], p=0·726). Serious adverse events were reported by 141 (27·9%) rivastigmine-treated patients and 155 (30·5%) patients on placebo; adverse events of all types were reported by 483 (95·6%) rivastigmine-treated patients and 472 (92·7%) placebo-treated patients. The predominant adverse events were cholinergic: the frequencies of nausea, vomiting, diarrhoea, and dizziness were two to four times higher in the rivastigmine group than in the placebo group. Interpretation: There was no significant benefit of rivastigmine on the progression rate to AD or on cognitive function over 4 years. The overall rate of progression from MCI to AD in this randomised clinical trial was much lower than predicted. Rivastigmine treatment was not associated with any significant safety concerns.

Original languageEnglish
Pages (from-to)501-512
Number of pages12
JournalThe Lancet Neurology
Volume6
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Rivastigmine
Alzheimer Disease
Placebos
Randomized Controlled Trials
Cognitive Dysfunction
Neurobehavioral Manifestations
National Institutes of Health (U.S.)
Dizziness

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment : the InDDEx study. / Feldman, Howard H.; Ferris, Steven; Winblad, Bengt; Sfikas, Nikolaos; Mancione, Linda; He, Yunsheng; Tekin, Sibel; Burns, Alistair; Cummings, Jeffrey; del Ser, Teodoro; Inzitari, Domenico; Orgogozo, Jean Marc; Sauer, Heinrich; Scheltens, Philip; Scarpini, Elio; Herrmann, Nathan; Farlow, Martin; Potkin, Steven; Charles, H. Cecil; Fox, Nick C.; Lane, Roger.

In: The Lancet Neurology, Vol. 6, No. 6, 06.2007, p. 501-512.

Research output: Contribution to journalArticle

Feldman, HH, Ferris, S, Winblad, B, Sfikas, N, Mancione, L, He, Y, Tekin, S, Burns, A, Cummings, J, del Ser, T, Inzitari, D, Orgogozo, JM, Sauer, H, Scheltens, P, Scarpini, E, Herrmann, N, Farlow, M, Potkin, S, Charles, HC, Fox, NC & Lane, R 2007, 'Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study', The Lancet Neurology, vol. 6, no. 6, pp. 501-512. https://doi.org/10.1016/S1474-4422(07)70109-6
Feldman, Howard H. ; Ferris, Steven ; Winblad, Bengt ; Sfikas, Nikolaos ; Mancione, Linda ; He, Yunsheng ; Tekin, Sibel ; Burns, Alistair ; Cummings, Jeffrey ; del Ser, Teodoro ; Inzitari, Domenico ; Orgogozo, Jean Marc ; Sauer, Heinrich ; Scheltens, Philip ; Scarpini, Elio ; Herrmann, Nathan ; Farlow, Martin ; Potkin, Steven ; Charles, H. Cecil ; Fox, Nick C. ; Lane, Roger. / Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment : the InDDEx study. In: The Lancet Neurology. 2007 ; Vol. 6, No. 6. pp. 501-512.
@article{619fcd1c6d174a70bbf32b0fea95841a,
title = "Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study",
abstract = "Objective: To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline. Methods: The study was a double-blind, randomised, placebo-controlled trial of up to 48 months. All patients had MCI operationally defined by having cognitive symptoms, a global clinical dementia rating stage of 0·5, a score of less than 9 on the New York University delayed paragraph recall test, and by not meeting the diagnostic criteria for AD. Primary efficacy variables were time to clinical diagnosis of AD, and change in performance on a cognitive test battery. This study is registered with the US National Institutes of Health clinical trials database (ClinicalTrials.gov), number NCT00000174. Findings: Of 1018 study patients enrolled, 508 were randomly assigned to rivastigmine and 510 to placebo; 17·3{\%} of patients on rivastigmine and 21·4{\%} on placebo progressed to AD (hazard ratio 0·85 [95{\%} CI 0·64-1·12]; p=0·225). There was no significant difference between the rivastigmine and placebo groups on the standardised Z score for the cognitive test battery measured as mean change from baseline to endpoint (-0·10 [95{\%} CI -0·63 to 0·44], p=0·726). Serious adverse events were reported by 141 (27·9{\%}) rivastigmine-treated patients and 155 (30·5{\%}) patients on placebo; adverse events of all types were reported by 483 (95·6{\%}) rivastigmine-treated patients and 472 (92·7{\%}) placebo-treated patients. The predominant adverse events were cholinergic: the frequencies of nausea, vomiting, diarrhoea, and dizziness were two to four times higher in the rivastigmine group than in the placebo group. Interpretation: There was no significant benefit of rivastigmine on the progression rate to AD or on cognitive function over 4 years. The overall rate of progression from MCI to AD in this randomised clinical trial was much lower than predicted. Rivastigmine treatment was not associated with any significant safety concerns.",
author = "Feldman, {Howard H.} and Steven Ferris and Bengt Winblad and Nikolaos Sfikas and Linda Mancione and Yunsheng He and Sibel Tekin and Alistair Burns and Jeffrey Cummings and {del Ser}, Teodoro and Domenico Inzitari and Orgogozo, {Jean Marc} and Heinrich Sauer and Philip Scheltens and Elio Scarpini and Nathan Herrmann and Martin Farlow and Steven Potkin and Charles, {H. Cecil} and Fox, {Nick C.} and Roger Lane",
year = "2007",
month = "6",
doi = "10.1016/S1474-4422(07)70109-6",
language = "English",
volume = "6",
pages = "501--512",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "6",

}

TY - JOUR

T1 - Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment

T2 - the InDDEx study

AU - Feldman, Howard H.

AU - Ferris, Steven

AU - Winblad, Bengt

AU - Sfikas, Nikolaos

AU - Mancione, Linda

AU - He, Yunsheng

AU - Tekin, Sibel

AU - Burns, Alistair

AU - Cummings, Jeffrey

AU - del Ser, Teodoro

AU - Inzitari, Domenico

AU - Orgogozo, Jean Marc

AU - Sauer, Heinrich

AU - Scheltens, Philip

AU - Scarpini, Elio

AU - Herrmann, Nathan

AU - Farlow, Martin

AU - Potkin, Steven

AU - Charles, H. Cecil

AU - Fox, Nick C.

AU - Lane, Roger

PY - 2007/6

Y1 - 2007/6

N2 - Objective: To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline. Methods: The study was a double-blind, randomised, placebo-controlled trial of up to 48 months. All patients had MCI operationally defined by having cognitive symptoms, a global clinical dementia rating stage of 0·5, a score of less than 9 on the New York University delayed paragraph recall test, and by not meeting the diagnostic criteria for AD. Primary efficacy variables were time to clinical diagnosis of AD, and change in performance on a cognitive test battery. This study is registered with the US National Institutes of Health clinical trials database (ClinicalTrials.gov), number NCT00000174. Findings: Of 1018 study patients enrolled, 508 were randomly assigned to rivastigmine and 510 to placebo; 17·3% of patients on rivastigmine and 21·4% on placebo progressed to AD (hazard ratio 0·85 [95% CI 0·64-1·12]; p=0·225). There was no significant difference between the rivastigmine and placebo groups on the standardised Z score for the cognitive test battery measured as mean change from baseline to endpoint (-0·10 [95% CI -0·63 to 0·44], p=0·726). Serious adverse events were reported by 141 (27·9%) rivastigmine-treated patients and 155 (30·5%) patients on placebo; adverse events of all types were reported by 483 (95·6%) rivastigmine-treated patients and 472 (92·7%) placebo-treated patients. The predominant adverse events were cholinergic: the frequencies of nausea, vomiting, diarrhoea, and dizziness were two to four times higher in the rivastigmine group than in the placebo group. Interpretation: There was no significant benefit of rivastigmine on the progression rate to AD or on cognitive function over 4 years. The overall rate of progression from MCI to AD in this randomised clinical trial was much lower than predicted. Rivastigmine treatment was not associated with any significant safety concerns.

AB - Objective: To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline. Methods: The study was a double-blind, randomised, placebo-controlled trial of up to 48 months. All patients had MCI operationally defined by having cognitive symptoms, a global clinical dementia rating stage of 0·5, a score of less than 9 on the New York University delayed paragraph recall test, and by not meeting the diagnostic criteria for AD. Primary efficacy variables were time to clinical diagnosis of AD, and change in performance on a cognitive test battery. This study is registered with the US National Institutes of Health clinical trials database (ClinicalTrials.gov), number NCT00000174. Findings: Of 1018 study patients enrolled, 508 were randomly assigned to rivastigmine and 510 to placebo; 17·3% of patients on rivastigmine and 21·4% on placebo progressed to AD (hazard ratio 0·85 [95% CI 0·64-1·12]; p=0·225). There was no significant difference between the rivastigmine and placebo groups on the standardised Z score for the cognitive test battery measured as mean change from baseline to endpoint (-0·10 [95% CI -0·63 to 0·44], p=0·726). Serious adverse events were reported by 141 (27·9%) rivastigmine-treated patients and 155 (30·5%) patients on placebo; adverse events of all types were reported by 483 (95·6%) rivastigmine-treated patients and 472 (92·7%) placebo-treated patients. The predominant adverse events were cholinergic: the frequencies of nausea, vomiting, diarrhoea, and dizziness were two to four times higher in the rivastigmine group than in the placebo group. Interpretation: There was no significant benefit of rivastigmine on the progression rate to AD or on cognitive function over 4 years. The overall rate of progression from MCI to AD in this randomised clinical trial was much lower than predicted. Rivastigmine treatment was not associated with any significant safety concerns.

UR - http://www.scopus.com/inward/record.url?scp=34248372938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248372938&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(07)70109-6

DO - 10.1016/S1474-4422(07)70109-6

M3 - Article

VL - 6

SP - 501

EP - 512

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 6

ER -